DAYBREAK Supports Zenkuda Filing and Extends Kodiak Platform
Kodiak Sciences reported that both Zenkuda and tabirafusp alfa tedromer met the one-year visual-acuity noninferiority endpoint versus aflibercept in the approximately 690-patient Phase 3 DAYBREAK study. Fifty-four percent of Zenkuda-treated patients reached a 24-week…
